Efficacy and safety of second- or third-line nab-paclitaxel + durvalumab in patients with advanced NSCLC (ABOUND.2L+)
Váldodahkkit: | Morgensztern, D, Govindan, R, Cobo, M, Ponce Aix, S, Postmus, PE, Lewanski, C, Bennouna, J, Fischer, J, Juan-Vidal, O, Stewart, D, Ardizzoni, A, Bhore, R, Wolfsteiner, M, Reck, M, Talbot, D, Ong, TJ |
---|---|
Materiálatiipa: | Conference item |
Giella: | English |
Almmustuhtton: |
Elsevier
2018
|
Geahča maid
-
Quality of life in patients with advanced NSCLC treated in second- or third-line with nab-paclitaxel + durvalumab: abound.2l+
Dahkki: Talbot, D, et al.
Almmustuhtton: (2018) -
Nab-paclitaxel + durvalumab as second- or third-line treatment of advanced NSCLC: results from ABOUND.2l+
Dahkki: Govindan, R, et al.
Almmustuhtton: (2017) -
ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)
Dahkki: Morgensztern, D, et al.
Almmustuhtton: (2017) -
nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)
Dahkki: Daniel Morgensztern, et al.
Almmustuhtton: (2021-02-01) -
Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer
Dahkki: Ponce Aix, S, et al.
Almmustuhtton: (2020)